logo
Wolford Appoints Deputy CEO, Completes Capital Increase

Wolford Appoints Deputy CEO, Completes Capital Increase

Yahoo17-07-2025
MILAN — Wolford AG has appointed Marco Pozzo its deputy chief executive officer.
At the same time, on Wednesday the luxury skinwear brand stated it has successfully completed a capital increase of 25 million euros, 'reinforcing the company's financial foundation to accelerate its strategic transformation.'
More from WWD
WWD Toasts Milan Men's Fashion Week With Cocktail Reception, Global Impact Council Dinner
Pitti Uomo Protagonists Show Summer Chic for Spring 2026
Caruso: Playful Elegance, Suits, Authenticity Are Here to Stay
The transaction, carried out via rights issue, resulted in the issuance of more than 5 million new shares at a subscription price of 4.80 euros per share, increasing the company's share capital to more than 71.4 million euros. This capital raise 'reflected the confidence of parent Lanvin Goup and other key investors in Wolford's vision and execution,' stated Wolford.
Pozzo has previously worked in leading design and luxury brands ranging from Ermenegildo Zegna and Alessi, to FontanaArte and Driade, holding executive roles internationally — from Mexico to Greater China — spearheading major retail and organizational expansions, as well as the digital transformation and the omnichannel strategy of the brands.
Regis Rimbert succeeded Silvia Azzali as the CEO of Wolford in the summer of 2024, but he left after only six months, as reported in January. This was a return to Wolford for Rimbert as he held senior management positions from 2009 to 2013 at the Austrian hosiery and innerwear company, driving its omnichannel transformation. Since Rimbert's exit there has been no CEO at the helm of Wolford.
Azzali had set in motion a reorganization of the company, planning its expansion and inking a string of collaborations with brands ranging from No. 21, Jonathan Simkhai and Mugler to Adidas, Alberta Ferretti and Etro, among others, on collections that included jumpsuits or bodysuits in addition to hosiery. In February 2023, Nao Takekoshi was named artistic director.
On her tours, Beyoncé has been seen wearing Wolford tights and bodysuits and her dancers, during the Cowboy Carter tour, wore matching denim chaps with Wolford x Etro paisley tattoo bodysuits.
Wolford marks its 75th anniversary this year as it was established in 1950 near the shores of Lake Constance in the city of Bregenz.
Since 2018, it has been part of the Lanvin Group — then called Fosun. Lanvin Group is publicly listed in New York, while Wolford is traded on the Vienna Stock Exchange.
As reported in April, Lanvin Group revenues fell 23 percent to 329 million euros last year. Losses widened to 189.3 million euros from 146.3 million euros a year earlier. Adjusted losses before interest, taxes, depreciation and amortization widened to $92.3 million from $64.2 million. Some of that represented organizational and operational changes at the company, which also owns Lanvin, St. John, Sergio Rossi and Caruso.
David Chan, executive president and chief financial officer of Lanvin Group, said on a conference call at the time that those adjusted losses included 14 million euros to 18 million euros to integrate Wolford's logistics.Best of WWD
EXCLUSIVE: Maje Names Charlotte Tasset Ferrec CEO
Nadja Swarovski Exits Family Company Amid Ongoing Corporate Shakeup
Aeffe MD Exits Fashion Group
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eddie Howe Clarifies Isak's Situation Ahead of Arsenal Clash
Eddie Howe Clarifies Isak's Situation Ahead of Arsenal Clash

Yahoo

time19 minutes ago

  • Yahoo

Eddie Howe Clarifies Isak's Situation Ahead of Arsenal Clash

Eddie Howe confirms no contract talks with Swedish striker amid Liverpool links Eddie Howe Clarifies Isak's Situation Ahead of Arsenal Clash Newcastle United manager Eddie Howe's responded to swirling rumors surrounding the future of Alexander Isak denying any current negotiations over contract renewal with the Swedish forward. No Contract Talks Yet Speaking ahead of Newcastle's pre season friendly against Arsenal, Howe stated: "To my knowledge, there're no ongoing negotiations over Isak's contract. That could happen later" Despite Isak still having three years left on his deal speculation surged this week after the 25 year old missed the club's Asia tour due to reported thigh injury. Behind the Scenes Talks? Multiple outlets including The Athletic & Daily Mail, claim Isak's informed the club he wants clarity on possible move with Liverpool reportedly keen on his signature. However, Howe remained firm but diplomatic: "Isak's been amazing for the team. He's loved in the dressing room. We'd like him to continue his journey with us" He admitted Isak's under pressure: "He knows he'll be in the headlines daily. That's not easy for anyone in this position" €170M Price Tag Set Reports suggest Newcastle've placed 170 million Euro price tag on Isak an amount widely seen as deal breaker for potential buyers.

Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment
Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment

Yahoo

time19 minutes ago

  • Yahoo

Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment

Eli Lilly recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a crucial therapeutic area. During the same period, LLY registered a 5% share price increase, notably outpacing the broader market's 1% rise over the past week. This uptrend in LLY's stock could be attributed to investors' optimism about donanemab's potential impact. Additionally, the company's collaboration with Gate Bioscience to develop novel therapies further strengthens its innovative capabilities, adding weight to its share price momentum amid broader market gains. We've spotted 2 risks for Eli Lilly you should be aware of, and 1 of them doesn't sit too well with us. Find companies with promising cash flow potential yet trading below their fair value. The recent positive opinion from the CHMP about Eli Lilly's Alzheimer's drug, donanemab, could significantly enhance the company's revenue and earnings forecasts. This development positions the company well for future growth, adding credibility to its strategic focus on expanding into high-demand therapeutic areas like oncology and immunology. Coupled with its collaboration with Gate Bioscience, these advances may provide substantial long-term benefits to the company's bottom line. Over the past five years, Eli Lilly's total return, which includes both share price growth and dividends, was a very large 473.44%. This long-term growth far outpaces the recent 1% rise in the broader market over the past year, bolstering investor confidence in the company's strategic trajectory and robust pipeline. In comparison to the US Pharmaceuticals industry, which saw a decline of 5.9% over the past year, Eli Lilly's sharp uptick in share price highlights its strong performance relative to industry peers. The company's earnings growth was a robust 80.9% over the past year, indicative of its potent execution in a challenging market. The current share price of US$812.69, when set against the analyst consensus price target of US$952.27, suggests there is room for potential growth. However, it also indicates investor caution, likely weighed down by concerns over competitive pressure and pricing dynamics. Investors might find reassurance in the company's ongoing manufacturing and R&D investments, which aim to mitigate risks and sustain growth in the coming years. Understand Eli Lilly's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

Vandals set fire to a mouse statue that's a TV star and mascot for a German broadcaster
Vandals set fire to a mouse statue that's a TV star and mascot for a German broadcaster

Washington Post

time21 minutes ago

  • Washington Post

Vandals set fire to a mouse statue that's a TV star and mascot for a German broadcaster

BERLIN — Vandals set fire to a mouse statue that's a TV star and mascot for children's programming at German broadcaster WDR, the television station said Saturday. The cartoon mouse, known only as 'Die Maus,' is the eponymous star of 'Die Sendung mit der Maus' (The Show with the Mouse) since it first aired in West Germany in 1971. Each short episode features other languages and educational segments.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store